WO2008108958A3 - Dérivés de benzimidazole et leurs procédés d'utilisation - Google Patents

Dérivés de benzimidazole et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2008108958A3
WO2008108958A3 PCT/US2008/002594 US2008002594W WO2008108958A3 WO 2008108958 A3 WO2008108958 A3 WO 2008108958A3 US 2008002594 W US2008002594 W US 2008002594W WO 2008108958 A3 WO2008108958 A3 WO 2008108958A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
benzimidazole derivatives
igt
impaired
Prior art date
Application number
PCT/US2008/002594
Other languages
English (en)
Other versions
WO2008108958A2 (fr
WO2008108958A8 (fr
Inventor
Robert G Aslantan
Jean E Lachowicz
Michael Y Berlin
Joyce J Hwa
Original Assignee
Schering Corp
Robert G Aslantan
Jean E Lachowicz
Michael Y Berlin
Joyce J Hwa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2008223513A priority Critical patent/AU2008223513A1/en
Priority to US12/527,500 priority patent/US20100144591A1/en
Priority to CN200880014373A priority patent/CN101674827A/zh
Priority to MX2009009416A priority patent/MX2009009416A/es
Priority to EP08714248A priority patent/EP2114402A2/fr
Priority to JP2009551714A priority patent/JP2010520201A/ja
Application filed by Schering Corp, Robert G Aslantan, Jean E Lachowicz, Michael Y Berlin, Joyce J Hwa filed Critical Schering Corp
Priority to BRPI0808707-5A priority patent/BRPI0808707A2/pt
Priority to CA002679809A priority patent/CA2679809A1/fr
Publication of WO2008108958A2 publication Critical patent/WO2008108958A2/fr
Publication of WO2008108958A3 publication Critical patent/WO2008108958A3/fr
Publication of WO2008108958A8 publication Critical patent/WO2008108958A8/fr
Priority to IL200639A priority patent/IL200639A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (I), des compositions comprenant ces composés et des procédés d'utilisation des composés pour traiter ou prévenir la douleur, le diabète, une complication diabétique, une intolérance au glucose ou une hyperglycémie modérée à jeun (HMJ) chez un patient.
PCT/US2008/002594 2007-03-02 2008-02-27 Dérivés de benzimidazole et leurs procédés d'utilisation WO2008108958A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US12/527,500 US20100144591A1 (en) 2007-03-02 2008-02-27 Benzimidazole derivatives and methods of use thereof
CN200880014373A CN101674827A (zh) 2007-03-02 2008-02-27 苯并咪唑衍生物及其使用方法
MX2009009416A MX2009009416A (es) 2007-03-02 2008-02-27 Derivados de bencimidazol y sus metodos de uso.
EP08714248A EP2114402A2 (fr) 2007-03-02 2008-02-27 Dérivés de benzimidazole et leurs procédés d'utilisation
JP2009551714A JP2010520201A (ja) 2007-03-02 2008-02-27 ベンズイミダゾール誘導体およびその使用方法
AU2008223513A AU2008223513A1 (en) 2007-03-02 2008-02-27 Benzimidazole derivatives and methods of use thereof
BRPI0808707-5A BRPI0808707A2 (pt) 2007-03-02 2008-02-27 Uso de derivados de benzimidazol e composição compreendendo os mesmos
CA002679809A CA2679809A1 (fr) 2007-03-02 2008-02-27 Derives de benzimidazole et leurs procedes d'utilisation
IL200639A IL200639A0 (en) 2007-03-02 2009-08-30 Benzimidazole derivatives and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90445307P 2007-03-02 2007-03-02
US60/904,453 2007-03-02

Publications (3)

Publication Number Publication Date
WO2008108958A2 WO2008108958A2 (fr) 2008-09-12
WO2008108958A3 true WO2008108958A3 (fr) 2009-05-07
WO2008108958A8 WO2008108958A8 (fr) 2009-08-13

Family

ID=39386454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002594 WO2008108958A2 (fr) 2007-03-02 2008-02-27 Dérivés de benzimidazole et leurs procédés d'utilisation

Country Status (18)

Country Link
US (1) US20100144591A1 (fr)
EP (1) EP2114402A2 (fr)
JP (1) JP2010520201A (fr)
KR (1) KR20090127902A (fr)
CN (1) CN101674827A (fr)
AR (1) AR065495A1 (fr)
AU (1) AU2008223513A1 (fr)
BR (1) BRPI0808707A2 (fr)
CA (1) CA2679809A1 (fr)
CL (1) CL2008000593A1 (fr)
EC (1) ECSP099612A (fr)
IL (1) IL200639A0 (fr)
MX (1) MX2009009416A (fr)
PE (1) PE20090111A1 (fr)
RU (1) RU2009136263A (fr)
TW (1) TW200843756A (fr)
WO (1) WO2008108958A2 (fr)
ZA (1) ZA200906062B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537998A (ja) * 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
AU2009296820B2 (en) * 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2404902A1 (fr) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
RU2542582C2 (ru) * 2009-11-18 2015-02-20 Астразенека Аб Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
DK2519522T3 (en) 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
WO2012020725A1 (fr) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
JP5790440B2 (ja) 2010-12-01 2015-10-07 住友化学株式会社 ピリミジン化合物およびその有害生物防除用途
MX339899B (es) * 2011-02-25 2016-06-16 Array Biopharma Inc Compuestos de triazolopiridina como inhibidores de pim cinasa.
JP2014114212A (ja) * 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
WO2012158117A1 (fr) * 2011-05-17 2012-11-22 Astrazeneca Ab Traitements combinés pour le traitement de la douleur
WO2012177852A1 (fr) 2011-06-24 2012-12-27 Arqule, Inc Composés d'imidazopyridinyle substitués
CN103748093B (zh) 2011-06-24 2016-06-01 艾科尔公司 被取代的咪唑并吡啶基-氨基吡啶化合物
WO2014031445A1 (fr) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole tétrahydropyrane
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
CN104860919B (zh) * 2015-03-26 2017-11-10 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途
WO2017082393A1 (fr) * 2015-11-12 2017-05-18 学校法人 聖マリアンナ医科大学 Agent prophylactique et thérapeutique contre le glaucome

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
WO2003059342A1 (fr) * 2002-01-11 2003-07-24 Abbott Laboratories Ligands de recepteur d'histamine-3 pour traiter des etats diabetiques
WO2003103669A1 (fr) * 2002-04-18 2003-12-18 Schering Corporation 1-(4-piperidinyl) benzimidazolones utilises en tant qu'antagonistes du recepteur h3 de l'histamine
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
WO2007035703A1 (fr) * 2005-09-20 2007-03-29 Schering Corporation La 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4, 5-b] pyridin-3-yl] piperidine, utile en tant qu'antagoniste de l'histamine h3
WO2007075555A2 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
WO2003059342A1 (fr) * 2002-01-11 2003-07-24 Abbott Laboratories Ligands de recepteur d'histamine-3 pour traiter des etats diabetiques
WO2003103669A1 (fr) * 2002-04-18 2003-12-18 Schering Corporation 1-(4-piperidinyl) benzimidazolones utilises en tant qu'antagonistes du recepteur h3 de l'histamine
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
WO2007035703A1 (fr) * 2005-09-20 2007-03-29 Schering Corporation La 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4, 5-b] pyridin-3-yl] piperidine, utile en tant qu'antagoniste de l'histamine h3
WO2007075555A2 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEERS M H ET AL: "Treatment of pain", THE MERCK MANUAL OF DIAGNOSIS AND THERAPY, WHITEHOUSE STATION, N.J. : MERCK RESEARCH LABORATORIES, vol. 18Eds, 1 January 2006 (2006-01-01), pages 1771 - 1777, XP002505251, ISBN: 978-0-911910-18-6 *
HANCOCK ARTHUR A ET AL: "Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 487, no. 1-3, 8 March 2004 (2004-03-08), pages 183 - 197, XP002509267, ISSN: 0014-2999 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518062B2 (en) 2009-07-16 2016-12-13 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Also Published As

Publication number Publication date
CN101674827A (zh) 2010-03-17
TW200843756A (en) 2008-11-16
JP2010520201A (ja) 2010-06-10
KR20090127902A (ko) 2009-12-14
AU2008223513A1 (en) 2008-09-12
EP2114402A2 (fr) 2009-11-11
RU2009136263A (ru) 2011-04-10
WO2008108958A2 (fr) 2008-09-12
WO2008108958A8 (fr) 2009-08-13
CL2008000593A1 (es) 2008-09-05
PE20090111A1 (es) 2009-02-26
US20100144591A1 (en) 2010-06-10
CA2679809A1 (fr) 2008-09-12
AR065495A1 (es) 2009-06-10
ZA200906062B (en) 2010-05-26
ECSP099612A (es) 2009-10-30
MX2009009416A (es) 2009-09-11
IL200639A0 (en) 2010-05-17
BRPI0808707A2 (pt) 2014-09-09

Similar Documents

Publication Publication Date Title
WO2008108958A3 (fr) Dérivés de benzimidazole et leurs procédés d'utilisation
WO2008108957A3 (fr) Dérivés pipéridines et leurs procédés d'utilisation
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP2217596B8 (fr) Dérivés hétérocycliques bicycliques et leur utilisation en tant que modulateurs de l'activite du gpr 119
WO2007128817A3 (fr) Dérivé insulinique
WO2005075425A3 (fr) Derives de bisaryluree
WO2007104789A3 (fr) Dérivés d'amyline
WO2009145456A3 (fr) Dérivés hétérocycliques
WO2008012227A3 (fr) Pyrazoles comme activateurs de glucokinase
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
MY152172A (en) Therapeutic agent for diabetes
AU2010212865A8 (en) SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2007127273A3 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
UA101166C2 (ru) Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
WO2011147951A8 (fr) Dérivés de cycloamino comme antagonistes du gpr119
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2009133099A3 (fr) Précurseurs de l'insuline pour le traitement du diabète
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2008116663A3 (fr) Dérivés de tétrahydro-naphtalène-amine substitués par un hétérocyclyle, leur préparation et utilisation en tant que médicaments
WO2009003719A3 (fr) Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments
WO2010121675A3 (fr) Thiazolyl-benzimidazoles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880014373.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008714248

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714248

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 579338

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200639

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008223513

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2679809

Country of ref document: CA

Ref document number: 2009551714

Country of ref document: JP

Ref document number: 09092684

Country of ref document: CO

Ref document number: 5133/CHENP/2009

Country of ref document: IN

Ref document number: PI20093611

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12009501685

Country of ref document: PH

Ref document number: MX/A/2009/009416

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008223513

Country of ref document: AU

Date of ref document: 20080227

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097020505

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009136263

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12527500

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0808707

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090902